The Fund supports networks of state health policy decision makers to help identify, inspire, and inform policy leaders.
The Milbank Memorial Fund supports two state leadership programs for legislative and executive branch state government officials committed to improving population health.
The Fund identifies and shares policy ideas and analysis to advance state health leadership, strong primary care, and sustainable health care costs.
Keep up with news and updates from the Milbank Memorial Fund. And read the latest blogs from our thought leaders, including Fund President Christopher F. Koller.
The Fund publishes The Milbank Quarterly, as well as reports, issues briefs, and case studies on topics important to health policy leaders.
The Milbank Memorial Fund is is a foundation that works to improve population health and health equity.
March 2013 (Volume 91)
Quarterly Article
Bhaven N. Sampat
Kristin Buterbaugh
Marcel Perl
March 2024
Mar 11, 2024
Feb 27, 2024
Back to The Milbank Quarterly
Context: The responsiveness of NIH (National Institutes of Health) funding to disease burden is a long-standing issue of policy interest. Previous analyses of this issue have been hindered by data constraints, have not specified channels through which the NIH funding process could be responsive to disease considerations, and have not examined differences across NIH institutes and centers.
Methods: We collected data from the NIH’s new RCDC (Research, Condition, and Disease Categorization) database on funding for 107 diseases in 2008 and linked these to data on deaths and hospitalizations for these diseases. We used RCDC data and information from another NIH database—RePORTER—to determine institute-specific funding for these diseases and also funding by award type. We used these data to examine the overall responsiveness of NIH funding to disease burden, within-institute responsiveness, and the responsiveness of different types of NIH awards.
Findings: Overall, we found a strong and statistically significant relationship between NIH funding and deaths and hospitalizations associated with a disease. We detected some evidence that more “applied” grant mechanisms—in particular, funding for clinical trials—are more responsive than other types of funding. We also found evidence of differences across institutes in their extent of responsiveness.
Conclusions: Overall, the data suggest that NIH funding is responsive to the two measures of disease burden. More applied grant mechanisms also may serve as “safety valves” in the allocation process, allowing Congress, disease advocacy groups, and others to apply pressure to address particular health priorities in a more fine-grained way than is possible through investigator-initiated “basic” research grants alone.
Author(s): Bhaven N. Sampat, Kristin Buterbaugh, and Marcel Perl
Keywords: National Institutes of Health (U.S.), resource allocation
Read on Wiley Online Library
Volume 91, Issue 1 (pages 163–185) DOI: 10.1111/milq.12005 Published in 2013
